Saluggia - October 22, 2019 - DiaSorin (FTSE MIB: DIA) announces the LIAISON HCV Ab FDA clearance for qualitative determination of specific hepatitis C antibodies in serum and plasma, available on LIAISON XL fully automated platform.

LIAISON HCV Ab is one of the key tests in the DiaSorin and Beckman Coulter strategic agreement to serve the US market with a complete panel of hepatitis and retrovirus tests.

Around 115 million individuals are positive for HCV and 80 million suffer from a chronic infection. Complications from chronic hepatitis C were the cause of around 1 million deaths in 2018; for this reason, HCV infection diagnosis is needed to prevent the spread of the infection and to optimize patients’ management.

The LIAISON HCV Ab test, as part of DiaSorin’s Hepatitis panel, will be available in the US market according to the strategic agreement signed with Beckman Coulter. This provides US customers access to the complete Hepatitis and HIV products on the LIAISON XL in connection with Beckman Coulter’s leading automation solutions.

Carlo Rosa, Chief Executive Officer of DiaSorin Group, commented, “The HCV test is one of the key products of our hepatitis and retrovirus catalogue to serve and enter the US market in alliance with Beckman Coulter.

As disclosed in our last Capital Market Day, this partnership is one of the pillars of our future growth and we are proud to collaborate with Beckman Coulter in this business opportunity. At the same time I’m convinced that our positioning as an infectious diseases player in the US market will allow us to furtherly penetrate the selected hospital labs where total laboratory automation is not required”.

DiaSorin

Headquartered in Italy and listed in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field. For over 50 years, the Company has been developing, producing and marketing reagent kits for IVD worldwide. The Group has a presence on the 5 continents with 25 companies, 5 foreign branches, 6 manufacturing facilities and 5 research centers throughout the world. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the “Diagnostic Specialist”.

For additional information, please contact:
Riccardo Fava
Corporate Vice President Communication & Investor Relations
Tel. +39.0161.487988
riccardo.fava@diasorin.it

Ines Di Terlizzi
Investor Relator
Tel. +39.0161.487567
ines.diterlizzi@diasorin.it